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Plant-derived natural products occupy an important position in the area of cancer chemotherapy. Molecules such as vincristine,
vinblastine, paclitaxel, camptothecin derivatives, epipodophyllotoxin, and so forth, are invaluable contributions of nature to
modern medicine. However, the quest to ﬁnd out novel therapeutic compounds for cancer treatment and management is a
never-ending venture; and diverse plant species are persistently being studied for identiﬁcation of prospective anticancer agents.
In this regard, Andrographis paniculata Nees, a well-known plant of Indian and Chinese traditional system of medicines, has
drawn attention of researchers in recent times. Andrographolide, the principal bioactive chemical constituent of the plant has
shown credible anticancer potential in various investigations around the globe. In vitro studies demonstrate the capability of the
compound of inducing cell-cycle arrest and apoptosis in a variety of cancer cells at diﬀerent concentrations. Andrographolide
also shows potent immunomodulatory and anti-angiogenic activities in tumorous tissues. Synthetic analogues of the compound
have also been created and analyzed, which have also shown similar activities. Although it is too early to predict its future in
cancer chemotherapy, the prologue strongly recommends further research on this molecule to assess its potential as a prospective
anticancer agent.
1.Introduction
1.1. The Anti-Neoplastic Phyto-Pharmacophores. The era
of chemotherapy began in 1940s with the ﬁrst use of
nitrogen mustards and antifolate drugs [1]. Thereafter,
cancer drug discovery and development have been the
major research endeavor around the globe. The quest to
ﬁnd new therapeutic candidate compounds from natural
biodiversity, particularly plants, has been the prime interest
amongst researchers. The search for anti-cancer agents
from plant sources started in earnest in 1950s with the
discoveryanddevelopmentofthevincaalkaloids,vinblastine
(velban) and vincristine (oncovin); and the isolation of
cytotoxic podophyllotoxins [2]. Vinca alkaloids (antimi-
totics, which form tubulin-alkaloid complexes and distort
the microtubule assembly of cancer cells) are generally
used in combination therapy with synthetic molecules
[3–5]. Most recent semi-synthetic analogues of these
agents are vinorelbine (navelbine) and vindesine (eldisine).
Another class of potent plant-derived anti-cancer agents
consists of topoisomerase II inhibitors. Etoposide (Vepesid)
and teniposide (Vumon) are semi-synthetic derivatives of
epipodophyllotoxin (isomer of podophyllotoxin) derived
from Podophyllum spp. (Podophyllum peltatum Linnaeus
and Podophyllum emodi Wallich). Most recent additions to
the armamentarium of plant-derived anti-cancer agents are
taxanes and camptothecins. Paclitaxel (commonly known
as Taxol) and the related semi-synthetic docetaxel (Tax-
otere) are currently being used in a large number of
cancer treatments [6]. Though discovered quite early in
drug discovery process [7], the development of these
molecules as clinically active agents required about 20–
30 years of dedicated research. Other molecules in clinical
use are homoharringtonine, isolated from the Chinese tree,
Cephalotaxus harringtonia var. drupacea (Sieb and Zucc.)
(family, Cephalotaxaceae) and elliptinium, a derivative of
ellipticine, isolated from species of several genera of the
Apocynaceae family, including Bleekeria vitensis A.C. Sm.,
a Fijian medicinal plant with reputed anti-cancer properties
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In addition to these molecules in clinical use, a few very
promising compounds with strong anti-cancer potential are
currently undergoing clinical trials. These include ﬂavopiri-
dol, combretastatins, 4-ipomeanol, colchicines, genistein,
lapachol, curcumin, and so forth. Flavopiridol is a synthetic
ﬂavone structurally based on alkaloid rohitukine found in
Amoora rohituka and Dysoxylum binectariferum (Maliaceae).
It is the most interesting plant-based compound in develop-
ment as it represents the ﬁrst cyclin dependent kinase (cdk)
inhibitortoentertheclinic[4].Thecombretastatins(isolated
from South African bush willow Combretum caﬀrum (Eckl.
& Zeyh.) Kuntze (family, Combretaceae)) are a family
of stilbenes, which act as anti-angiogenic agents, causing
vascularshutdownintumorsandresultingintumornecrosis
[2]. The demand for these anti-cancer compounds is ever
increasing as strongly reﬂected in the annual sales of these
compounds. Camptothecin derivatives account for nearly a
billion dollars annually, paclitaxel and its derivatives have
sales exceeding towards two billion dollars per annum [8, 9].
It is fascinating to note that almost all the above-
mentioned drugs have a very strong ethno-botanical back-
ground, which strengthens the fact that by exploring the
folkloric knowledge, several new compounds may be discov-
ered. Traditional medicinal systems have always contributed
chemical entities with attractive scaﬀolds for drug discovery
[10–12]. A recent example of this approach to discover novel
anticancer dugs is the formation of a library of 531 cytotoxic
natural products derived from traditional Chinese medicine
(TCM)[13]. However, this is just a glimpse of what the plant
biodiversity holds for us in the area of anti-cancer research.
While many plant-derived molecules have shown wonders
as chemotherapeutic agents, there are a large number of
compounds that need to be explored as prospective anti-
canceragents.Thisarticlefocusesontheanticancerpotential
of “andrographolide”, the major bioactive constituent of
Andrographis paniculata, a well-known plant of Ayurveda
and TCM.
1.2. The Plant—Andrographis Paniculata Nees. Andrographis
paniculata (Burm. F.) Nees (family, Acanthaceae) grows
widely in many Asian countries such as China, India,
Thailand and Sri Lanka [14] and has a long history
of therapeutic usage in Indian and Oriental medicine
[15, 16]. The herb is oﬃcial in Indian Pharmacopoeia
[17] as a predominant constituent of at least 26 Ayurvedic
formulations used to treat liver disorders. It is one of the
herbs, which can be used to treat neoplasm as mentioned in
ancient Ayurvedic literature [18]. Andrographis paniculata
is reported as a cold property herb in TCM and is used
to get rid of body heat and to expel toxins. The plant is
particularly known for its extremely bitter properties (often
called king of bitters) and is used traditionally as a remedy
against common cold, dysentery, fever, tonsillitis, diarrhoea,
liver diseases, inﬂammation, herpes, and so forth [19–21].
The traditional uses and pharmacological aspects of A.
paniculata have been well-documented in an extensive
review recently [22]. A number of active principles are
reported from the plant, which mainly include diterpene
lactones, ﬂavonoids and polyphenols [23, 24]. However,
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Figure 1:Structureoftheprinciplephytochemicalcompoundof A.
paniculata Nees, andrographolide.
the prime constituent andrographolide has been is mainly
attributed for its therapeutic properties. Diterpenoid lactone
andrographolide (C20H30O5) is the principle compound
found in A. paniculata, which is mainly concentrated in
leaves and can be easily isolated from the crude plant extracts
as crystalline solid [25, 26]. The structure of the compound
has been elucidated by X-Ray crystallographic analysis and
the molecular stereochemistry, bond distances, bond angles,
andsoforthallweredetermined[27].Chemicallydesignated
as (3-[2-[decahydro-6-hydroxy-5-(hydroxymethyl)-5, 8-
adimethyl-2-methylene-1-napthalenyl] ethylidene] dihydro-
4-hydroxy-2(3H)-furanone), andrographolide (Figure 1)
exhibits extraordinarily vast range of biological activities
[28–33]. In recent past, the compound is reported for
its anti-tumor, anti-HIV and cardio-protective properties
[15,34–39]. However, it shows a weakanti-microbial activity
against bacteria and viruses [40].
1.3. Anti-Cancer Potential of Andrographolide. Most of the
anti-cancer agents employed in modern medicine aim at
inhibiting the proliferation of cancer cells by inducing
apoptosis, necrosis, cell-cycle arrest or cell diﬀerentiation;
others might involve immunomodulatory activity, by trig-
gering body’s own immune system against these cells. The
compounds that inhibit multiple procancer events are of
greaterinterestastheyaremorelikelytoinhibitawiderrange
of cancers under great variety of circumstances [41]. In this
context, andrographolide presents a strong candidature as a
therapeutic anticancer pharmacophore as it exhibits a dual
property, acting both directly and indirectly on the cancer
cells [42], which will be discussed in detail in this article.
1.3.1. Cytotoxic Activity against Cancer Cells. Methanolic
extract of A. paniculata has shown signiﬁcant toxicity against
KB (human epidermoid leukemia) and P388 (lymphocytic
leukemia)celllines[43].Bioactivityguidedchromatographic
fractionation led to the isolation of pure andrographolide,
which was also highly toxic to the above-mentioned cell
lines. This was one of the ﬁrst signiﬁcant demonstrations of
cytotoxicpotentialofandrographolide.Potentcytotoxicityin
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cell lines including drug resistant cancer cells has also been
reported in another excellent work [37]. The cytotoxic prop-
erty has been attributed to the ability of andrographolide to
inhibit proliferation and induce apoptosis in cancer cells.
1.3.2. Induction of Cell-Cycle Arrest. Various studies have
demonstrated that andrographolide eﬀectively induces cell-
cycle arrest in cancer cells at G0/G1 stage [44]. A study with
human acute myeloid leukemic HL-60 cells, demonstrated a
27% increase in G0/G1 phase cells and signiﬁcant decrease in
cells at S and G2/M phase after andrographolide treatment
(12μg/ml) for 36h [45]. Andrographolide inhibits cell-
cycle progression by modulating the expression of cell-cycle
related proteins. The induction of cell-cycle arrest at G0/G1
phase is mainly due to the induction of cell-cycle inhibitory
proteins p16, p21, p27 associated with decreased expression
of cyclin A, cyclin D, CDK4 and CDK2, required for G1 to S
transition [37, 46]. Shi et al. [46] have demonstrated almost
complete inhibition of human colorectal carcinoma Lovo
cells as attained by andrographolide treatment (10–30μM).
Here the increased levels of p21 after andrographolide treat-
ment (3.75-fold) are of particular interest as decreased p21
expression has been associated with aggressive phenotype in
many cancers. The molecular target of andrographolide that
blocks the G1 stage still needs to be determined.
1.3.3. Induction of Apoptosis. Andrographolide activates the
extrinsic death receptor pathway (including caspase-3 and
caspase-8)andinducesapoptoticcelldeathincertainhuman
cancer cell types [47]. In some cell types (type 1), the
activation of caspase-8 is suﬃcient to activate the eﬀector
caspases (caspase 3/7), whereas in majority of cell types
(type 2), the eﬀector caspase activation requires ampliﬁca-
tion of signal through mitochondria. This was elucidated
through another study on three diﬀerent human cancer lines
(including cervical, breast and hepatoma cell lines) by Zhou
et al. [48], in which around 8-fold increase in the caspase 3/7
activity was observed after treatment with andrographolide
(50μM for 6h), against control [48]. The pro-apoptotic Bcl-
2 family members (bid and bax) are the key mediators in
relaying cell death signaling initiated by andrographolide
from caspase-8 to mitochondria and then to downstream
eﬀector caspase 3, eventually leading to cytochrome c
release and apoptotic cell death [48, 49]. A recent work
demonstrates that tumor necrosis factor-α (TNF-α) related
apoptosis inducing ligand (TRAIL—an important member
of extrinsic apoptosis pathway) was signiﬁcantly enhanced
in various human cancer cell lines after treatment with
andrographolide, [50]. TRAIL is an important anti-cancer
agent,asitcanpreferentiallykillcancercellsamongstnormal
cells and therefore is a very important molecule in cancer
research [51]. Some kinds of cancer cells develop resistance
towards TRAIL, which is a major constraint in TRAIL
mediated apoptosis. Thus, compounds that enhance TRAIL
expression or are able to re-sensitize resistant cancer cells to
TRAIL induced apoptosis are extremely valuable [52, 53].
In this context andrographolide is a promising molecule
as it could enhance TRAIL expression via up-regulation of
death receptor (DR-4) and also re-sensitize resistant cancer
cells to TRAIL-induce apoptosis [50]. Further studies in this
direction might help in developing andrographolide as a
sensitizer for TRAIL induced apoptosis in various kinds of
tumors.
Studies have demonstrated that andrographolide is also
eﬀective in combination therapy. Andrographolide increased
the apoptosis rate in multidrug resistant cancer cells, when
used in combination treatment along with other anticancer
agents like 5-ﬂorouracil (5-FU), adriamycin and cisplatin
[54].Andrographolideindividuallyaswellasincombination
with 5-FU was assessed in treatment of human carcinoma
HCC cells, where it could induce synergistic apoptosis [55].
Apartfrominducingapoptosisincancercells,thecompound
is also able to induce cell diﬀerentiation in proliferating
cancer cells. The myeloid leukemia (M1) cells of mouse were
directed to diﬀerentiate into phagocytes following treatment
with andrographolide. This particular activity is rarelyfound
in plant-derived anti-cancer agents and thus is of particular
interest [56].
1.3.4. Immunostimulating Properties. Andrographis panicu-
lata is known to exert a strong immunomodulatory eﬀect
as it has been observed that the alcohol extract of the plant
as well as isolated andrographolide are able to induce sig-
niﬁcant stimulation of both “antigen speciﬁc” and “antigen
nonspeciﬁc” types of immune responses in mice, showing
eﬀectiveness against a variety of infectious and oncogenic
(cancer causing) agents [57, 58]. Factors like (TNF-α),
interleukin-2 (IL-2), interferon-γ (IFN-γ) and natural killer
(NK) cells play an important role in conferring protection
against neoplastic factors. Andrographolide plays a role in
regulating the production of these factors, thus acting in
a circuitous manner on the cancer cells. Administration
of andrographolide led to enhanced production of TNF-
α and expression of CD markers, eventually increasing the
cytotoxicactivityoflymphocytesagainstcancercells[37].An
increased proliferation of human peripheral blood lympho-
cytes(HPBLs)wasobservedafterandrographolidetreatment
(1μM for 48h), owing to enhanced IL-2 production and
ultimately the immune response against cancer cells [59].
In vivo experiments show that antibody-dependent cellular
toxicity, mitogen induced proliferation of bone marrow cells
and production of Il-2 and IFN-γ was elevated on treatment
withandrographolideinnormalaswellascarcinomabearing
animals [60]. Andrographolide stimulated the production
of cytotoxic T lymphocytes inhibiting tumor growth in
animals [61]. When administered in combination with
other neutraceuticals, andrographolide caused an increase in
function of NK cells and TNF-α thus resulting in improved
clinical outcomes in patients with late stage cancers of
diﬀerent types [62]. Thus the compound in addition to
conferring direct toxicity to cancer cells; modulates the host
immune system against these cells.
1.3.5. Anti-Inﬂammatory and Anti-Angiogenic Activity. Both
A. paniculata plant extract and andrographolide are known
to have an anti-inﬂammatory potential [63, 64]. Inﬂamma-
tion is considered as a critical component of tumor progres-
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inﬂammatory cells. This has been elucidated in an excellent
review [65], which also emphasizes on anti-inﬂammatory
therapeutic approaches for cancer treatment. Shen et al. [32]
suggested the prevention of production of reactive oxygen
species(ROS)byandrographolideasthepossiblemechanism
of its anti-inﬂammatory eﬀect. Andrographolide treatment
inhibits nuclear factorkappa B (NF-κB) binding to DNA and
thus reducing the expression of pro-inﬂammatory proteins
such as cycloxygenase 2 (Cox-2) and nitric-oxide synthase
(NOS) [66–69]. An important landmark in deciphering the
mechanism of action of andrographolide was the ﬁnding
that andrographolide reduces cysteine 62 of p50 (a major
subunit of NF-kB transcription factors), thus blocking
their binding to the promoters of their target genes [39,
68]. A major constraint in chemotherapy is the acquired
resistance of cancer cells to various chemotherapeutic agents
by activation of NF-kB that promotes cell survival [70].
Thus andrographolide as an inhibitor of NF-κB, might also
be used to sensitize cancer cells to overcome such kind of
resistance. Andrographolide also inhibits Erk 1/2a n dA k t
signaling, thus restraining the chemo-tactic migration of
macrophages on inﬂammation site [71–73]. Inhibition of
Erk signaling also leads to inhibition of v-Src oncoprotein
mediated transformation, which is strongly associated with
cancer initiation and progression [71].
Cancer cells are known to induce angiogenesis for
continuous supply of nutrients to the proliferating cells.
As angiogenesis is triggered in response to chronic inﬂam-
mation, there is a direct relation between inﬂammation,
carcinogenesis and angiogenesis. Therefore, owing to its
excellent anti-inﬂammatory activity, andrographolide has
been evaluated for its anti-angiogenic potential as well. As
an anti-angiogenic prospect, andrographolide could success-
fully inhibit the tumor speciﬁc capillary sprouting without
damaging the pre-existing vasculature. Andrographolide
administration also down-regulated the production of vari-
ousangiogenicfactorslikevascularendothelialgrowthfactor
(VEGF), nitric oxide (NO) and pro-inﬂammatory cytokines
and elevated the levels of anti-angiogenic factors like IL-
2 and tissue inhibitor of metalloproteinase (TIMP-1) in
vitro as well as in vivo [74]. VEGF is by and large used by
cancer cells as a survival factor and the inhibitory activity
of andrographolide on VEGF levels has been veriﬁed [34].
A schematic diagram depicting the multitarget potential of
andrographolide is presented as Figure 2.
1.3.6. Chemo-Protective Potential. Andrographolide exhibits
selectivecytotoxicityagainstvariouscancercells,asdescribed
earlier in the article. However, the compound has also
shown a chemo-protective potential towards normal cells
in a few studies. The chemo-protective potential of plant
extract against chemo-toxicity including carcinogenicity has
been described earlier [75]. Andrographolide in a dose
dependent manner inhibited IFN-γ and IL-2 production
in murine thymocytes induced by concanavaline A. It
also prevented cell apoptosis induced by drugs like hydro-
cortisone [76] .T h ep r o t e c t i v ee ﬀect of andrographolide
against cyclophosphamide induced urothelial toxicity [77]
and hexachlorocyclohexane induced oxidative injury [78]
has been reported. Andrographolide is eﬀective against a
large number of hepatotoxins, which might be due to its
ability to activate antioxidant enzymes that catalyze reaction
of oxidants in severe liver damage. The hepatoprotective
eﬀect of the compound was found comparable to that
of silymarin, when tested both in vitro and in vivo [79,
80]. These studies support the fact that A. paniculata is
used in Ayurvedic formulations to treat liver disorders.
Thus, in addition to inducing cytotoxicity to cancer cells
directly or indirectly, andrographolide can also prevent the
cytotoxicity to normal cells induced by various agents.
Chen et al. [81] have described protective function of
andrographolide on human umbilical vascular endothelial
cells (HUVECs) from GF deprivation-induced apoptosis via
enhancement of PI3K-Akt activity. Here, andrographolide
suppressed mitochondria mediated apoptosis by inhibiting
cytochrome c release to cytosol. In another ﬁnding, human
vascular endothelial cells were protected from adhesion of
gastric cancer cells by andrographolide through blocking
of E-selectin expression [82]. E-selectin is modulated by
NF-κB, thus demonstrating the eﬀect of andrographolide
treatment. However, andrographolide treatment can also
induce expression of CYP1A subfamily of cytochrome P450
family of enzymes, which are involved in metabolism of a
plethora of xenobiotics, and thus this interaction may be
clinically signiﬁcant [83]. Thus, further studies to determine
the eﬀect on the compound on cytochrome P450 enzymes
are fairly imperative.
2. Analoguesof Andrographolide
In addition to the naturally found andrographolide, re-
searchers have been successful in synthesizing andrographol-
ide derivatives that have also displayed anti-cancer activities
[84]. By parallel solution phase synthesis, Mang et al.
[85] have generated a 360 membered natural product
library starting from andrographolide. Naturally occurring
andrographolide (Figure 1) contains: (i) an α-alkylidene-c-
butyrolactonemoiety,(ii)twodoublebondsδ8(17) andδ12(13)
and (iii) three hydroxyls at C-3, C-19 and C-14. Of the three
hydroxyls, the one at C-14 is allylic, while others at C-3
and C-19 are secondary and primary, respectively [86]. The
intact γ-butyrolactone ring, the double bonds between C-
12 and C-13, C-8 and C-17 and hydroxyl group at C-14,
are primarily responsible for the cytotoxic activity of the
compound. Modiﬁcations made to this primary skeleton of
andrographolide may improve its anti-tumor activity [36,
87]. Three analogues (3,19-isopropylideneandrographolide;
14-acetyl-3, 19-isopropylideneandrographolide and 14-acet-
ylandrographolide) were synthesized by Jada et al. [36]
employingandrographolideasthestartingmaterial,ofwhich
14-acetylandrographolide was signiﬁcantly more potent
against many cancer cell lines when compared with the
parent compound. However, the mechanism of inducing
cell-cycle arrest was diﬀerent from andrographolide. This
research group has successfully developed new benzylidene
derivatives of andrographolide [3,19-(2-bromobenzylidene)
andrographolide and 3,19-(3-chloro-4-ﬂuorobenzylidene)
andrographolide], which are more cytotoxic and potent thanEvidence-Based Complementary and Alternative Medicine 5
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Figure 2: Eﬀect of andrographolide treatment on cancer cells. Cancer is a multifaceted disease with complex processes and requires a
multi-target therapeutic approach to battle it. A similar kind of action is displayed by andrographolide as it modulates various biochemical
pathways of cancer cells thereby inhibiting the tumor growth. The compound exerts cytotoxic eﬀect on various cancer cell types in a time
and dose dependent manner. Factors required for tumor progression, nourishment and metastasis are down regulated, that is, cyclins A,
D, Cdk2, Cdk4, NF-κB, VEGF, E-selectin, VCAM, Akt, TNF, Bcl2, and so forth. On the other hand tumor suppressor elements like p53,
caspases, inhibitory proteins p21, p16, p27, and so forth are up regulated as observed in various studies to investigate anti-cancer potential
of andrographolide. Up regulation of death receptor 4 to facilitate TRAIL induced apoptosis is of signiﬁcant interest. The cumulative eﬀect
of all these factorial events leads to inhibition of growth in cancer cells. The alphabets placed adjacent to the petals refer to the reference
numbers of articles. a [35, 45, 47, 49, 50]; b [49, 50, 60, 66, 68]; c [60, 62]; d [82]; e [37, 46, 87]; f [71–73]; g [34, 37, 45, 48]; h [34, 60, 74].
andrographolide [88]. Another semi-synthetic analogue of
andrographolide, DRF 3188 was found to have a better anti-
cancer activity on the cell-cycle of MCF-7 breast cancer
line by a similar mechanism as andrographolide [87]. The
eﬀect was almost comparable for both compounds, in vitro
as well as in vivo. Novel family of potent and speciﬁc α-
glucosidase inhibitors has been synthesized by using andro-
grapholide as the parent molecule [86]. These compounds
havethepotentialtobedevelopedasantitumoragents.These
results are supported by a diﬀerent ﬁnding, where it was
demonstrated that the succinoyl ester of andrographolide
signiﬁcantly inhibited proprotein convertases and thus dis-
played potent antiviral activities against HIV-1 and HIV-2
[89]. These results emphasize that some of the derivatives of
andrographolide might bemuch morepotent thattheparent
compounditselfandcallforadedicatedlineofinvestigations
to prove their potential.
3. CurrentStateofAffairsandFutureDirections
There has been a signiﬁcant rise in the number of studies
deciphering various aspects of anti-neoplastic activity of
andrographolide around the globe. However, most of the
data is based on in vitro cellular toxicity assays. Concrete
information based on mouse models of cancer is lacking
and there is a dearth of clinical evidence. Although andro-
grapholide has been subjected to clinical trials for treatment
against HIV and acute upper respiratory tract infection
[38, 90], clinical data regarding its anti-cancer activity is still
awaited. More studies on the pharmacokinetic properties of
the compound need to be performed. Therapeutic eﬃcacy of
a drug is reﬂected by its bioavailability and poor solubility of
andrographolide in water aﬀects its bioavailability. Recently
an inclusion technique has been developed to modify its
physical and chemical properties so as to increase its
bioavailability as well as prevent its hydrolysis in neutral and
alkaline environment of gastrointestinal tract [91]. However,
when taken in the form of an extract (Kan Jang), andro-
grapholide is readily absorbed in blood (maximum plasma
concentrations reached after 1.5–2hr of oral administration)
[92]. It is suggested that P-glycoprotein participates in the
intestinal absorption of andrographolide [93]. The available
information on the metabolism of the compound reﬂects
that metabolic fate of andrographolide in humans after
oral administration might involve a sulphonate reaction
at C-12 [94]. Structural illucidation of metabolites after
oral administration of andrographolide have shown sulphate
compounds and sulphonic acid adducts [95].6 Evidence-Based Complementary and Alternative Medicine
The available information is mostly in bits and pieces,
which needs to be compiled and assessed for carrying
out more appropriate studies towards establishing andro-
grapholide as a prospective anti-cancer agent. The molecule
has shown a broad-range anti-proliferative activity on a
variety cancer cell lines including breast cancer, colon cancer,
hepatoma, cervical cancer, leukemia, prostrate cancer and
many more. However it was found most eﬀective against
colon cancer cell lines [36, 37, 44, 46, 59], followed by
prostrate cancer and breast cancer. Amongst various breast
cancer cell lines also, the MCF-7 cell lines were found
most sensitive. As the colorectal and colon cancer cells
are observed to be more sensitive towards andrographolide
treatment, it would be worthy to conduct more studies on
colon cancer using andrographolide as the prospective drug.
The precise mechanism of action of the compound also
needs to be decoded, which is possible with the current
technological advances in our hands.
4. Conclusion
The hunt for alternative and complementary medicine is
an ongoing process in the area of cancer research, where
A. paniculata Nees, a renowned plant in South-Asian tradi-
tional medicine has recently attracted much attention owing
to its anti-cancer properties. The principle phytochemical
constituent of the plant, andrographolide, has shown signiﬁ-
cant anti-neoplastic and immunomodulatory activities in a
number of studies performed in recent times. It is a well-
established fact that an integrated approach is needed to
manage cancer and a compound or a group of compounds
that can inﬂuence multiple biochemical pathways related to
tumorigenesis are of prime interest in cancer chemotherapy.
With reference to Ayurveda, medicines work in synergy to
nourish body as a whole and thus several organ systems
are aﬀected at a time. Andrographis paniculata is cited in
Ayurveda as a plant with anti-cancer properties and it is
easy to presume the action of andrographolide on similar
principles. The compound is able to induce a G0/G1 cell-
cycle arrest in various kinds of cancer cells, activate the
death receptor pathways, induce TRAIL mediated apopto-
sis, activate p53 via enhanced phosphorylation and cause
inhibition of NF-κB transcriptional factors and various
angiogenic factors. It also exerts strong immunomodulatory
eﬀects against cancer cells in addition to its cytotoxic eﬀects;
a property which is similar to other anticancer agents
including doxorubicin, mitomycin, cisplatin, and so forth.
Apart from acting on various pathways to obliterate cancer
cells; it also exerts a protective eﬀect on normal cells saving
them from induced toxicity, in comparison to the contrary
eﬀect against cancer cells. These characteristics make it an
interesting molecule for further research. In addition to the
naturally found andrographolide, semi-synthetic analogues
of the compound have been synthesized, some of which have
also shown strong anti-cancer properties.
However, a lot of investigation needs to be done before
establishing it as a prospective chemotherapeutic agent. For
instance, the exact mechanism of action of andrographolide
has yet to be determined and toxicity of the compound
to higher animals and humans needs to be established. It
should be remembered that a number of naturally derived
agents have entered the clinical trials and terminated due
to lack of eﬃcacy and largely due to unacceptable toxicity.
Traditionally, the screening of compounds by performing in
vitro bioassays on a number of cancer cell lines has led to the
selection of promising compounds that are headed to pre-
clinical and clinical studies. On that basis, andrographolide
and its semi-synthetic derivatives are interesting prospects,
which can also provide a lead for novel anti-cancer drug
synthesis. Summing up, andrographolide puts forward a
strongcandidatureasaprospectiveplant-derivedanti-cancer
entity that needs to be thoroughly investigated for its anti-
cancer potential.
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